Efficacy and safety of ipragliflozin treatment for type 2 diabetes:a Meta-analysis
10.3969/j.issn.1006-5725.2017.19.038
- VernacularTitle:ipragliflozin治疗2型糖尿病有效性及安全性的Meta分析
- Author:
Zhiqiong HE
1
;
li Yan WANG
;
Maoqing HU
;
Lin ZHANG
Author Information
1. 610041 成都市,成都中医药大学第三附属医院,四川省糖尿病防治中心糖尿病科
- Keywords:
type 2 diabetes;
ipragliflozin;
Meta analysis
- From:
The Journal of Practical Medicine
2017;33(19):3299-3303
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the efficacy and safety of ipragliflozin ,a sodium glucose cotransporter 2 (SGLT2)inhibitor,for the treatment of type 2 diabetes. Methods Pubmed,the Cochrane Library,EMbase,CBM and CNKI databases was searched to identify randomized controlled trials(RCTs)pertinent to of ipragliflozin. The risk of bias of the included RCTs was assessed according to the Cochrane Handbook for Systematic Reviews of Inter-ventions Version 5.1.The RevMan 5.3 software was used for Meta-analysis. Results Ten RCTs with 2,390 partici-pants were included,Meta analysis showed that ipragliflozin was more effective than placebo in improving HbA1c level,and could concurrently reduce body weight,blood pressure,and the fasting plasma glucose(FPG)but not increase the risk of hypoglycemia. There were no statistically significant differences in the occurrence of urinary tract infection and genital infection as well as serious adverse events. Conclusion As a safe method ,ipragliflozin can effectively improve the HbA1c level in type 2 diabetes,help patients lose weight and reduce blood pressure.
